These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32033928)

  • 1. Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients With Acute Promyelocytic Leukemia.
    Rasekh EO; Elsayed GM; Madney Y; El Gammal MM
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):156-167. PubMed ID: 32033928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
    Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre'.
    Deka RR; Naseem S; Bhatia P; Binota J; Sonam P; Rana P; Malhotra P; Varma N
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):416-423. PubMed ID: 34987015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
    Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
    Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
    Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
    Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
    Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
    Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
    Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
    Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
    Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No prognostic significance of normalized copy number of PML-RARA transcript at diagnosis in patients with acute promyelocytic leukemia.
    Rasekh EO; Elsayed GM; Fathy S
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):119-125. PubMed ID: 32735792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review.
    Beitinjaneh A; Jang S; Roukoz H; Majhail NS
    Leuk Res; 2010 Jul; 34(7):831-6. PubMed ID: 20096459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia].
    Zhu YM; Liu YF; Zhang SJ; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):371-4. PubMed ID: 17939400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
    Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
    Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
    Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
    Kutny MA; Moser BK; Laumann K; Feusner JH; Gamis A; Gregory J; Larson RA; Powell BL; Stock W; Willman CL; Woods WG; Meshinchi S
    Pediatr Blood Cancer; 2012 Oct; 59(4):662-7. PubMed ID: 22378655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
    Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.